Imatinib plus atezolizumab versus imatinib alone for advanced GIST
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign consent for the study
- Your GIST diagnosis is confirmed by a pathology test (GIST in biopsy tissue)
- Your cancer is advanced and measurable, and it has grown despite at least imatinib, sunitinib, and regorafenib
- Your general health is good enough for treatment (ECOG 0–1) and blood/organ tests meet set minimums
- You can do study visits/tests and take medicines as required
- If you can get pregnant (or are a person who could get someone pregnant), you must use reliable birth control and (for pregnancy-capable patients) have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
Hear when a new Unresectable Gastrointestinal Stromal Tumor (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.